January 11, 2012
Anyone attending an FDA Advisory Committee meeting will likely discern right away that the job of serving in the capacity as a member is probably not terribly exciting. You have to travel from where you live, review mountains of data, … Continue reading →
January 10, 2012
As 2011 ended, there was a great deal of looking back at events of the year. As it affected new medical products, FierceBiotech reported on Friday that drug approvals during the year increased to 30 last year. Now as we … Continue reading →
October 5, 2011
This week a number of people took note when the FDA announced the issuance of a report that outlined eight new proposals to increase transparency by allowing greater access to the agency’s compliance and enforcement data. The eight proposals are … Continue reading →
May 18, 2011
Last week at the Reuter’s Health Summit held in New York, Janet Woodcock, the head of the Center for Drug Evaluation and Research was quoted as saying that she expected drug approvals to increase this year, but that the financial … Continue reading →
April 12, 2011
Every so often, I check in to see how the agency is faring when it comes to Advisory Committee transparency. The last time I did a chart like this several months ago, CDER and CBER figured in for having about … Continue reading →